Tag: 2020
ObsEva SA hosts live symposium and presents oral communication at the SEUD Online Week November 3 – 6, 2020
Geneva, Switzerland and Boston, MA – 2 November, 2020 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical…
ObsEva SA Presented Two Late-Breaking Posters at the ASRM 2020 Virtual Scientific Congress October 17-21
Geneva, Switzerland and Boston, MA – October 22, 2020 – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company developing and…
ObsEva SA Presented Nolasiban Poster at the ASRM 2020 Virtual Scientific Congress October 17-21
Geneva, Switzerland and Boston, MA – October 20, 2020 – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company developing and…
ObsEva SA to present at the H.C Wainwright 22nd Annual Global Investment Virtual Conference, September 14-16, 2020
Geneva, Switzerland and Boston, MA – September 8, 2020 – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company developing and…
ObsEva Announces $20.0 Million Underwritten Offering and Concurrent Private Placement Priced At-The-Market of Common Shares and 15-Month Purchase Warrants for Potential Additional Gross Proceeds of $23.9 Million
GENEVA, Switzerland and BOSTON, MA (September 3, 2020) – ObsEva SA (NASDAQ: OBSV) (SIX: OBSN) (“ObsEva” or the “Company”), a…
ObsEva SA to present at the Wedbush PacGrow Healthcare Virtual Conference, August 11 – 12, 2020
Geneva, Switzerland and Boston, MA – August 7, 2020 – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company developing and…
ObsEva Announces Second Quarter 2020 Financial Results and Business Update
Primary endpoint successfully met in Phase 3 PRIMROSE 1 trial of linzagolix for the treatment of heavy menstrual bleeding due…
Q2 Half Year Report 2020
ObsEva SA Awarded Clinical Science Award for Oral Presentation at ESHRE Virtual 36th Annual Meeting, July 2020
Geneva, Switzerland and Boston, MA – July 15, 2020 – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company developing and…